on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Reports Earnings Growth in First Half of 2025
In the first half of 2025, Eckert & Ziegler SE saw a slight increase in sales, reaching €148.8 million, a 2% rise compared to the previous year. The group's adjusted EBIT showed a 9% uplift, amounting to €35.4 million. Net income experienced a notable 19% increase, totaling €21.4 million or €1.03 per share.
The company's Medical segment performed well, with sales increasing to €80.5 million, primarily driven by pharmaceutical radioisotopes. However, the Isotope Products segment faced a sales decline of approximately 10%, recording €68.3 million due to seasonal and product group changes.
The company confirmed its 2025 forecast, expecting around €320 million in sales and €78 million in EBIT before special items.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news